Kategori: Nyheder

Wave Life Sciences annoncerer positive resultater fra fase 1b/2a SELECT-HD-forsøget med den første kliniske demonstration af allel-selektiv mutant Huntingtin-sænkning i Huntingtons sygdom

Today, Wave Life Sciences announced positive results from SELECT-HD, our Phase 1b/2a placebo-controlled trial evaluating the investigational therapy WVE-003. These results demonstrate that WVE-003 selectively lowers toxic, mutant huntingtin (mHTT) […]

PTC offentliggjorde i dag lovende 12-måneders resultater fra deres fase 2 PIVOT-HD-studie med oral PTC518  

At Month 12, mutant Huntingtin (mHTT) in the blood was lowered by 22% and 43% respectively for 5mg and 10mg doses. A similar result was seen in cerebrospinal fluid, where […]

Sage Therapeutics fase 2-studie forstærker den kognitive påvirkning af Huntingtons sygdom

Earlier this week Sage Therapeutics announced the results of their SURVEYOR study which quantified the cognitive impact of Huntington’s Disease.  Using the HD-Cognitive Assessment Battery (HD-CAB) they measured the difference […]

Opdatering fra Mellemøsten og Nordafrika

IHA President Svein Olaf Olsen was keynote speaker on Huntington’s Disease at the MENA Congress for Rare Diseases in Abu Dhabi last month. He spoke of the urgent need to […]

FDA giver uniQure betegnelsen Regenerative Medicine Advance Therapy (RMAT)

I dag er vi meget glade i Huntington-samfundet. Meddelelsen fra Uniqure om, at virksomheden har modtaget Regenerative Medicine Advanced Therapy (RMAT) "Designation for Investigational Gene Therapy AMT-130 [...]

Gratis online psykoterapiprogram for mennesker med HS

Doctors at the University of Reading (UK) have developed a free online psychotherapy programme for people with Huntington’s Disease.  It’s part of a research project that looks at how people […]

En ny forening for Huntingtons sygdom får støtte i Pakistan - HDSOP

Founding of the Huntington’s Disease Society of Pakistan April 24th 2024 Last week another national association was created.  The Huntington’s Disease Society of Pakistan (HDSOP) joined the growing  list of […]

SOM Biotech afslutter rekrutteringsprocessen i fase IIb-studiet af behandling af chorea ved Huntingtons sygdom

SOM Biotech, en klinisk fase lægemiddelopdagelses- og udviklingsvirksomhed baseret på en unik proprietær kunstig intelligensplatform (SOMAIPRO®), er glad for at kunne meddele, at rekrutteringen af den kliniske fase IIb [...].

Prilenia planlægger at indsende ansøgning om markedsføringstilladelse i EU for pridopidin til behandling af Huntingtons sygdom

Prilenia announced today that they plan to submit a Marketing Authorization Application in the EU for the use of Pridopidine in the treatment of Huntington’s Disease. According to Dr. Michael […]

Gennembrud repræsenterer et nyt håb for HS-patienter

Scientists from the Weizmann Institute in Israel have published the results of an animal study which holds tremendous promise for the treatment of Huntington’s Disease.  They have discovered that two […]